Ruane Cunniff & Goldfarb Increased Irsa Inversiones Y Rep S A (IRS) Stake, Bioanalytical Systems (BASI) Shorts Up By 45.25%

May 31, 2017 - By Ellis Scott

Ruane Cunniff & Goldfarb Inc increased Irsa Inversiones Y Rep S A (IRS) stake by 76.26% reported in 2016Q4 SEC filing. Ruane Cunniff & Goldfarb Inc acquired 182,857 shares as Irsa Inversiones Y Rep S A (IRS)’s stock rose 11.75%. The Ruane Cunniff & Goldfarb Inc holds 422,650 shares with $7.79 million value, up from 239,793 last quarter. Irsa Inversiones Y Rep S A now has $1.43B valuation. The stock rose 1.27% or $0.31 reaching $24.71 per share. About 25,449 shares traded. Irsa Inversiones y Rprsntcins SA (ADR) (NYSE:IRS) has risen 79.62% since May 31, 2016 and is uptrending. It has outperformed by 62.92% the S&P500.

Bioanalytical Systems Incorporated (NASDAQ:BASI) had an increase of 45.25% in short interest. BASI’s SI was 38,200 shares in May as released by FINRA. Its up 45.25% from 26,300 shares previously. With 25,400 avg volume, 2 days are for Bioanalytical Systems Incorporated (NASDAQ:BASI)’s short sellers to cover BASI’s short positions. The SI to Bioanalytical Systems Incorporated’s float is 0.58%. About 1,657 shares traded. Bioanalytical Systems, Inc. (NASDAQ:BASI) has risen 61.39% since May 31, 2016 and is uptrending. It has outperformed by 44.69% the S&P500.

Investors sentiment decreased to 0.4 in Q4 2016. Its down 3.60, from 4 in 2016Q3. It turned negative, as 2 investors sold Bioanalytical Systems, Inc. shares while 3 reduced holdings. 1 funds opened positions while 1 raised stakes. 195,764 shares or 58.45% less from 471,194 shares in 2016Q3 were reported. Renaissance Technologies Lc invested 0% of its portfolio in Bioanalytical Systems, Inc. (NASDAQ:BASI). Acadian Asset Mngmt Lc owns 1,500 shares for 0% of their portfolio. Dimensional Fund L P stated it has 0% of its portfolio in Bioanalytical Systems, Inc. (NASDAQ:BASI). Vanguard Incorporated has invested 0% in Bioanalytical Systems, Inc. (NASDAQ:BASI). Citadel Limited Liability Co invested in 0% or 14,983 shares. Blackrock Fund Advsrs has invested 0% in Bioanalytical Systems, Inc. (NASDAQ:BASI). North Star Asset Management has 20,000 shares. Barclays Public Ltd Co invested in 0% or 83 shares. 10,082 were accumulated by Goldman Sachs Gp. 1 are held by Financial Bank Of America De. State Street Corp holds 0% of its portfolio in Bioanalytical Systems, Inc. (NASDAQ:BASI) for 10,200 shares. Jpmorgan Chase And Communication reported 0% stake.

Bioanalytical systems, Inc. is an international contract research firm providing drug discovery and development services and analytical instruments. The company has market cap of $13.10 million. The Firm operates in two divisions: contract research services and research products. It currently has negative earnings. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies.